Kyntra Bio, Inc.
KYNB
Get informed when a big investor buys or sells
+ FollowMarket Cap$36.69M
Close$
$10.66
91.6% upside
Current Fair Value
91.6% upsideUndervalued by 91.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $36.69 Million |
|---|---|
| Enterprise Value | $-8,533,814.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $45.37 |
| Beta | 1.05 |
| Outstanding Shares | 4,048,000 |
Return
| Return on Equity | -2249.41% |
|---|---|
| Return on Assets | 181.24% |
| Return on Invested Capital | -79.59% |
Valuation & Multiples
| P/E Ratio | 0.11 |
|---|---|
| PEG | -0.04 |
| Price to Sales | 5.57 |
| Price to Book Ratio | -1.86 |
| Enterprise Value to Revenue | -1.85 |
| Enterprise Value to EBIT | 0.16 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.63 |
| Debt to Equity | -0.67 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-3.18
Average shareholder expectationRevenue Estimate
$2.09 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-3.66
Average shareholder expectationRevenue Estimate
$1.77 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About FibroGen Inc
34 employees
CEO: Enrique Conterno Kyntra Bio, Inc. is a biopharmaceutical enterprise focused on the entire spectrum of therapeutic innovation, from discovering new compounds to developing and commercializing them. Leveraging profound insights into hypoxia-inducible facto...